盲炳
06-17

$MRK 20250620 77.0 PUT$ 我開倉了$MRK 20250620 77.0 PUT$  ,來看看我最新分享的訂單！6月17日CDE官网显示默沙东Clesrovimab注射液上市申请拟优先审评，这极具投机潜力。从市场角度，呼吸道合胞病毒（RSV）对新生儿和婴儿威胁大，是一岁以下健康婴儿住院主因 ，该药物预防下呼吸道感染的需求迫切，市场广阔。从药物优势看，它是预防性长效单抗，单次给药，不受婴儿体重限制，便捷性远超同类。其关键研究数据亮眼，多项试验表明能大幅降低感染和住院率，获批上市后有望快速抢占市场，值得參與！
MRK PUT
06-17 22:50
US20250620 77.0
SidePrice | FilledRealized P&L
Sell
Open
0.21
2Lot(s)
--
Closed
Merck

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

  • Top
  • Latest
  • DeltaDrift
    ·06-19
    如果成功獲批，該藥物的市場份額將大大提升，這將對MRK的股價產生積極影響。
    Reply
    Report